Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin

Abstract : We attempted to prepare a subcutaneous pharmaceutical form of warfarin based on a suspension or poly(ε-caprolactone) microparticles to improve patient adherence. The warfarin suspension had a mean particle size of 20.0 μm and in vitro release close to 100% in 72 h. Microparticle size and encapsulation efficiencies ranged from 54.0 to 80.0 μm and 37.0 to 47.0%, respectively. After 72 h, warfarin microparticles exhibited in vitro drug release ranging from 62.0 to 80.0%. Warfarin subcutaneous dosage forms were administered to rabbits. Plasma concentration of warfarin was determined and biological activity was measured by prothrombin time monitoring. The observed relative bioavailabilities calculated from plasma concentrations and prothrombin times were 54.2 and 92.1%, and 61.8 and 61.4% for suspension and microparticles, respectively.
Type de document :
Article dans une revue
International Journal of Pharmaceutics, Elsevier, 2012, 431 (1-2), pp.33 - 38. 〈10.1016/j.ijpharm.2012.03.053〉
Liste complète des métadonnées

https://hal.univ-lorraine.fr/hal-01491914
Contributeur : Cithefor Ul <>
Soumis le : vendredi 17 mars 2017 - 15:55:30
Dernière modification le : jeudi 8 février 2018 - 15:56:35

Identifiants

Collections

Citation

J. Scala-Bertola, L. Javot, A. Camargo, F. Bonneaux, T. Lecompte, et al.. Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. International Journal of Pharmaceutics, Elsevier, 2012, 431 (1-2), pp.33 - 38. 〈10.1016/j.ijpharm.2012.03.053〉. 〈hal-01491914〉

Partager

Métriques

Consultations de la notice

27